

RECEIVED

COPY OF PAPERS  
ORIGINALLY FILED

AUG 06 2002

1644

Please type a plus sign (+) inside this box →


+

TECH CENTER 1600/2900

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

 <p><b>TRANSMITTAL FORM</b></p> <p>(to be used for all correspondence after initial filing)</p>		<b>Application Number</b>	09/844,544
		<b>Filing Date</b>	April 27, 2001
		<b>First Named Inventor</b>	ZENG, DEFU
		<b>Group Art Unit</b>	1644
		<b>Examiner Name</b>	DIBRINO, MARIANNE
<b>Total Number of Pages in This Submission</b>	4	<b>Attorney Docket Number</b>	STAN-190

**ENCLOSURES (check all that apply)**

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Change of Correspondence Address	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Certified Copy of Priority Documents	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<b>Remarks</b>	

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm or Individual Name	PAMELA J. SHERWOOD, Reg. No. 36,677	
Signature		
Date	July 24, 2002	

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: July 24, 2002.

Typed or printed name	Susan M. Alessi	Date	July 24, 2002
Signature			

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

AUG 06 2002

USSN: 09/844,544

#5  
9nd

## CERTIFICATE OF MAILING

TECH CENTER 1600/2900

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231.

Typed or Printed Name	Susan M. Alessi		
Signature	<i>Susan M. Alessi</i>	Date	July 24, 2002

<b>Restriction Election</b>  Address to: Assistant Commissioner for Patents Washington, D.C. 20231	Attorney Docket	STAN-190
	First Named Inventor	D. Zeng
	Application Number	09/844,544
	Filing Date	April 27, 2001
	Group Art Unit	1644
	Examiner Name	M. Dibrino
<b>Title: Methods for Inhibition of Polyclonal B Cell and Immunoglobulin Class Switching to Pathogenic Autoantibodies by Blocking CD1-Mediated Interactions</b>		

Sir:

This paper is responsive to the Restriction Requirement dated June 25, 2002, which set a one-month period for response.

In response, Applicants elect the invention of Group III, Claims 1, 2, 4-10, 12 and 13 for examination, with traverse. Applicants respectfully submit that the class of CD1 blocking agents represents a generic claim, and that the election of antibodies should be an election of species in the group, not a separate invention.

While 35 U.S.C. 121 provides that restriction may be required to one of two or more independent and distinct, 37 CFR 1.141 provides that a reasonable number of species may still be claimed in one application if the other conditions of the rule are met.

As discussed in MPEP 806.04(a), species, while usually independent, may be related under the particular disclosure. Where inventions as disclosed and claimed are both (A) species under a claimed genus and (B) related, then the question of restriction must be determined by both the practice applicable to election of species and the practice applicable to other types of restrictions such as those covered in MPEP § 806.05 - § 806.05(i).

It is not possible to define a generic claim with that precision existing in the case of a general claim (MPEP 806.04(d)). In general, a generic claim should include no material element additional to those recited in the species claims, and must comprehend within its confines the